Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine

Cancer Science

Volumn 103, Issue 5, 2012, Pages 889-896

  Hayashi, Tomomi ^a   Ding, Qiang ^a   Kuwahata, Taisaku ^a   Maeda, Koki ^a   Miyazaki, Yumi ^a   Matsubara, Shuichiro ^a   Obara, Toru ^a   Natsugoe, Shoji ^a   Takao, Sonshin ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BROXURIDINE; CD133 ANTIGEN; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG RESPONSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; HUMANS; INTERFERON-ALPHA; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PEPTIDES;

EID: 84860237519     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02235.x     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
4. Dean M. Cancer stem cells: implications for cancer causation and therapy resistance. Discov Med 2005; 5: 278-82.
5. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-45.
6. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
7. Beier D, Hau P, Proescholdt M et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-5.
8. Zhao P, Lu Y, Jiang X, Li X. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci 2011; 102: 1107-11.
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
10. Florek M, Haase M, Marzesco AM et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005; 319: 15-26.
11. Ferrandina G, Bonanno G, Pierelli L et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008; 18: 506-14.
12. Zhu Z, Hao X, Yan M et al. Cancer stem/progenitor cells are highly enriched in CD133 + CD44 + population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-78.
13. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10.
14. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-5.
15. Haraguchi N, Ohkuma M, Sakashita H et al. CD133 + CD44 + population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008; 15: 2927-33.
16. Morikawa K, Okudo K, Haraguchi N et al. Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity. Cancer Sci 2011; 102: 1164-70.
17. Maeda S, Shinchi H, Kurahara H et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98: 1389-97.
18. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
19. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
20. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Ann Rev Biochem 1998; 67: 227-64.
21. Tagliaferri P, Caraglia M, Budillon A et al. New pharmacokinetic and pharmacodynamic tools for interferon-α (IFN-α) treatment of human cancer. Cancer Immunol Immunother 2005; 54: 1-10.
22. Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002; 13: 111-8.
23. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-48.
24. Challen GA, Little MH. A side order of stem cells: the SP phenotype. Stem Cells 2006; 24: 3-12.
25. Moserle L, Indraccolo S, Ghisi M et al. The side population of ovarian cancer cells is a primary target of IFN-α antitumor effects. Cancer Res 2008; 68: 5658-68.
26. Solorzano CC, Hwang R, Baker CH et al. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 2003; 9: 1858-67.
27. Miyamoto A, Umeshita K, Sakon M et al. Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. J Gastroenterol Hepatol 2000; 15: 1447-51.
28. Wada H, Nagano H, Yamamoto H et al. Combination therapy of interferon- and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncol Rep 2007; 18: 801-9.
29. Sparano JA, Lipsitz S, Wadler S et al. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-α in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol 1996; 19: 546-51.
30. Wagener DJ, Wils JA, Kok TC, Planting A, Couvreur ML, Baron B. Results of a randomized phase II study of cisplatin plus 5-fluorouracjl versus cisplatin plus 5-fluorouracil with a-interferon in metastatic pancreatic cancer. An EORTC gastrointestinal tract cancer group trial. Eur J Cancer 2002; 38: 648-53.
31. Martínez CC, Alvarez SN, Vicente OV, García RJ, Pascual CF, Campos AM. In vitro and in vivo effect of IFN-αlpha on B16F10 melanoma in two models: subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice). Biomed Pharmacother 2009; 63: 305-12.
32. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2', 2'-difluoro-2'-deoxycytidine). Cancer Res 1990; 50: 4417-22.
33. Essers MA, Offner S, Blanco Bose WE et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature 2009; 458: 904-8.
34. Persano L, Moserle L, Esposito G et al. Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis 2009; 30: 851-60.
35. Joshi S, Kaur S, Redig AJ et al. Type 1 interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci USA 2009; 106: 12097-102.
36. Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-33.
37. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101: 781-6.
38. Chiba T, Kita K, Zheng YW et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-51.
39. Haraguchi N, Utsunomiya T, Inoue H et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 506-13.
40. Lim R, Knight B, Patel K, McHutchison JG, Yeoh GC, Olynyk JK. Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. Hepatology 2006; 43: 1074-83.
41. Mueller MT, Hermann PC, Witthauer J et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009; 137: 1102-13.